



Why Is This Debate So Controversial?

David R. Holmes, Jr., MD, MACC


TCTAP 2021- VIRTUAL


April 21-25, 2021

The following relationships exist related to this presentation:

None

Two Very Different Procedures





What do we know

- We do not outgrow coronary artery disease
- We need to learn how to manage it
- Patients' expectations vary
 - Specific endpoints
 - Timeline
- Optimal medical therapy is of foundational importance

Controversies

A long history

- CASS Trial 1974-1979
 - 1,492 patients with LMCA disease (>50%)
 - Overall CABG better than medical therapy except moderate stenosis and normal or only mildly abnormal LV in which case outcomes were similar and not significantly different

Controversies

A long history

- 1978 Gruentzig performed POBA in 50 patients over the next 18 months
 - Acute/subacute, vessel closure, elastic recoil, re-narrowing
 - Maybe hold off for now

Controversies

- Heterogeneity of anatomic groups
- Subsets of patients – registries vs. RCTs
- Length of follow up
 - SYNTAXES – 10 year follow up – no difference in all cause mortality
- What is best endpoint and at what time
 - Death, cardiac death, stroke (NOBLE??), MI, Repeat intervention, Quality of Life, Return to work, days in hospital
- Is there catch up?

Controversies

- Stent strategy – DK Crush versus other
- Stent type
- Graft strategy – RCT – more sternal wound complications but no significant difference – death/events
- Long term therapy
- Protected left main or not
- Coronary dominance

LMCA





Questions & Discussion